Editorial
L
eft ventricular assist devices (LVADs) are efficient pumps that assist the circulation. They are rapidly evolving and being inserted into an increasing number of patients with advanced heart failure either as a bridge to transplantation or increasingly as destination therapy. The epidemic of heart failure is only likely to worsen as the population ages. Although medical therapy has improved the survival of many, there remain a large group of patients who, despite optimal medical therapy, deteriorate and develop advanced heart failure. Although heart transplantation is highly successful for these patients, unfortunately the number of useable donor hearts is totally inadequate for the population that need them.
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The number of pumps being implanted has particularly increased since the introduction of the continuous-flow (CF) pumps, which have almost replaced the pulsatile pumps. They have far better survival and longer durability but are associated with significant bleeding complications.
Gastrointestinal bleeding is a huge problem after LVAD implantation. Its incidence has been estimated between 15% and 61%, 1 and a meta-analysis has shown a pooled prevalence of 23% in LVAD recipients. 2 The CF pumps are associated with a much higher incidence of gastrointestinal bleeding compared with the earlier pulsatile LVADs (where the incidence was ≈10%), and patients are 4.5 to 10× more likely to experience gastrointestinal bleeding depending on the series.
2-4 LVAD recipients also have a greater severity of gastrointestinal bleeds than the general population, requiring an average of 2 to 4 U of packed red blood cells per admission and have a high rate of rebleeding of around 35%. 4 LVADassociated LVAD gastrointestinal bleeding is associated with significant morbidity, hospital readmissions, and cost. The increased morbidity includes the need for blood transfusions, extended hospital stays, multiple readmissions, and overall mortality. Gastrointestinal bleeding also complicates subsequent heart transplantation because multiple blood transfusions in these LVAD recipients can lead to the development of circulating antibodies, reducing the probability of a donor organ match.
Although the CF pumps require both aspirin and coumadin, whereas the pulsatile pumps only require aspirin, the higher gastrointestinal bleeding incidence seen does not seem because of anticoagulation alone. Indeed the rate of gastrointestinal bleeding in patients with CF-LVADs is much higher (65 per 100 patient-years) than in patients with mechanical valves who are also on aspirin and warfarin (2.60-4.6 per 100 patient-years) and than the 8% that occurs in patients receiving triple antithrombotic therapy (aspirin, clopidogrel, and warfarin) suggesting a direct contribution of the pump toward bleeding. 4 It has been hypothesized that the continuous-flow pump itself directly leads to increased gastrointestinal bleeding, but the exact mechanism has been poorly understood. Physiological changes related to a lack of pulsatility and sheer stresses from the pump are likely to play an important role. The anatomic location of bleeding is predominantly upper gastrointestinal in origin, and most of them are from angiodysplastic lesions.
In this edition of Circulation Research, Kang et al 5 provide some important new evidence. In this 3-center study, they provide the first evidence that LVAD support itself directly causes gastrointestinal angiodysplasia. Although in small numbers, they performed an autopsy study in deceased humans, cows, and sheep supported with a continuous-flow LVAD. In comparison with controls after LVAD support, large dilated angiodysplastic lesions were seen within the intestinal submucosa. Abnormal vascular architecture was observed in the submucosa of the jejunum of human patients, cows, and sheep supported with a continuous-flow LVAD with significantly higher intestinal vascularity after LVAD support versus controls (5.2±1.0% versus 2.1±0.4%; P=0.004). This 3-species study suggests that angiodysplasia is directly related to the LVAD.
It also suggests that LVAD-associated angiodysplasia is a distinct pathology. Clinical evidence would also support this. Whereas typical age-related angiodysplasia occurs most commonly in the right colon (which has the greatest luminal diameter and wall tension), the majority of LVAD-associated angiodysplasia and bleeding occurs in the small bowel and upper gastrointestinal tract. Further clinical evidence that LVAD-associated gastrointestinal bleeding is a distinct pathophysiology unrelated to preexisting gastrointestinal lesions or anticoagulation is that the majority of patients who develop bleeding do not have a history of gastrointestinal bleeding, 6 a history of gastrointestinal bleeding is not a risk factor for bleeding post-VAD implantation, 2 antiplatelet therapy is not a risk factor for LVAD-associated bleeding, and most patients who bleed present with a therapeutic or subtherapeutic showed that gastrointestinal bleeding from angiodysplatic lesions in patients with LVADs is associated with an increased number of bleeding events compared with gastrointestinal bleeding from angiodysplatic lesions in non-LVAD patients (2.07 versus 1.23; P=0.01), a higher number of bleeding events per year, an increased incidence of major bleeding, increased rates of transfusion, and that they cause increased risk and length of stay after LVAD implantation of >45 days. They also showed the majority of gastrointestinal bleeding from angiodysplatic lesions in LVAD patients to be in the upper gastrointestinal tract. Wever-Pinzon et al 8 found a significant association between a low pulsatile state and smooth muscle dilation and consequently, arteriovenous dilation. Animal studies have demonstrated that continuous-flow physiology leads to microvascular hypoperfusion, even if a physiological mean blood pressure is maintained, and this is believed to lead to localized hypoxia, vascular dilatation, and angiodysplasia as well. 4 A chronic narrow pulse pressure system might alter neurovascular physiology, increase sympathetic tone, intraluminal pressure, and smooth muscle relaxation with resultant distention of submucosal venous plexus, and angioectasia formation.
Hematologic changes are also seen in these patients, such as impaired platelet aggregation, which is independent of anticoagulation because although aspirin or dipyridamole do impair platelet function, platelet aggregation is also impaired in patients on LVADs not taking anticoagulation. 4 Impaired platelet aggregation is partially caused by the interactions with artificial material and turbulent blood flow through the LVAD. Platelets tend to exhibit increased sensitivity to sheer stress, and VADs cause significant platelet injury, impaired aggregation, and adherence. 1 Furthermore, antiplatelet therapy disrupts prostaglandin synthesis, thus exposing the gastric mucosa to high acid concentrations.
In parallel, in their study, Kang et al 5 evaluated plasma samples from 41 patients with continuous-flow LVAD for pathological von Willebrand factor (vWF) degradation. vWF circulates in the blood as the largest soluble multimeric protein (>20 000 Kd). 9 These highest molecular weight multimers play a major role in primary hemostasis by binding to the glycoprotein Ib-V-IX and IIb/IIIa receptors of platelets and collagen to form a clot and close a leakage in the vascular endothelium. 9 vWF is cleaved by a metalloprotease (ADAMTS13), particularly under conditions of high shear stress. 9, 10 Structural changes can be induced by high shear stress in the von Willebrand molecule exposing the bond between amino acids 842 and 843 to ADAMTS13. 10 This results in the loss of the largest von Willebrand multimers, which are most effective in platelet-mediated hemostasis resulting in acquired type 2 vWS, which is characterized by an acquired bleeding diathesis.
In paired samples before and after LVAD implantation, Kang et al 5 showed LVAD support caused significant degradation of the high-molecular-weight vWF multimers (−9±1%; P<0.0001) and accumulation of low-molecular-weight multimers (+40±5%; P<0.0001) and vWF degradation fragments (+53±6%; P<0.0001). This has been shown before [9] [10] [11] in LVAD recipients, and the profile of degradation was consistent with the profile that others have observed. It seems that patients receiving CF-LVADs loose the high-molecular-weight multimers, whereas the levels are normal in patients with pulsatile LVADs, and levels reverse after explanation of the CF-LVAD because of transplantation or myocardial recovery. 10 There is evidence to suggest that vWF may play a role in regulating angiogenesis via VEGFR2 (vascular endothelial growth factors receptor-2) and angiopoietin-2. 7, 12 Angiodysplasia occurs in Willebrand disease patients who lack the high-molecular-weight vWF and vWF deficiency is associated with increased VEGFR2 and angiopoietin-2. 12 Angiogenic factors, such as VEGF and the angiopoietins, orchestrate signaling pathways that promote endothelial cell migration and proliferation and ultimately the formation of a new vessel. 12 VEGF is a specific mitogen for endothelial cells linked to normal and pathological angiogenesis, and increased expression of VEGF occurs in non-VAD human 
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September 29, 2017 colonic angiodysplasia. Elevated angiopoietin-2 has been demonstrated in patients with LVAD. 13 Angiopoietin-2 disrupts vital intercellular connections that are associated with vessel maturation and induces endothelial inflammation and abnormal angiogenesis resulting in tortuous, fragile vessels that are prone to bleeding. 13 Furthermore, angiotensin II signaling through the angiotensin type receptors induces expression of angiopoietin-2, and ACE (angiotensin-converting enzyme inhibitor) or ARB (angiotensin II receptor blocker) therapy has been shown to reduce the risk of gastrointestinal bleeding caused by arteriovenous malformations in patients with LVADs. 14 The findings in this study by Kang et al may have wider implications for the pathogenesis of other bleeding complications that occur after LVAD implantation. A recent study 15 studied hypervascularity in the nasal mucosa of patients with CF-LVADs and found nasal hypervascularity to be strongly associated with gastrointestinal bleeding. In fact, all the subjects who experienced clinical gastrointestinal bleeding had nasal hypervascularity, whereas no gastrointestinal bleeding episodes occurred in subjects with normal nasal mucosa, suggesting that VAD hypervascularity is a systemic process. Hence, these findings may have implications for other LVADrelated bleeding, such as hemorrhagic stroke.
Conclusions
In conclusion, Kang et al 5 showed across 3 species that abnormal vascular architecture develops during continuous-flow LVAD support and that the LVAD results in angiodysplastic lesions (Figure) . They show that LVAD-associated angiodysplasia may be its own distinct pathology with different pathophysiologic triggers than age-related angiodysplasia. They also showed continuous-flow LVAD support to cause the degradation of high-molecular-weight vWF multimers and accumulation of low-molecular-weight multimers and vWF degradation fragments suggesting that LVAD support itself alters systemic angiogenic signals, which may contribute to the development of gastrointestinal angiodysplasia and bleeding (Figure) . These important pathophysiologic insights are likely to help address the important complication of gastrointestinal bleeding and may have wider implications for other LVADassociated bleeding.
